GH secreting pituitary adenoma
Conditions
Interventions
1:Acetaminophen
2:TMS (1Hz, 20min) and acetaminophen
3:TMS (10Hz, 20min) and acetaminophen
Sponsors
Huashan Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with GH tumor who have undergone transnasal pituitary tumor resection or craniotomy for pituitary tumor resection in the past (3 months or more) and biochemical remission were achieved; 2. Aged between 18 and 60 years; 3. Regardless of gender; 4. The patient still has headaches after the operation, the duration of each attack is more than 4 hours, and the attack is more than 3 times per month; 5. The patient is in a headache attack period; 6. A clear consciousness, able to understand and sign an informed consent form. GH tumor is diagnosed as below: Preoperative glucose tolerance test (OGTT) simultaneously determines that the nadir value of GH is greater than 1ng/ml, and the level of IGF-1 is greater than the upper limit of the age-sex-matched normal value. Biochemical remission is determined as below: The random GH value or the nadir GH value during OGTT is less than 1ng/ml, and the IGF-1 level is within the normal range of age and gender matching;
Exclusion criteria
Exclusion criteria: 1. Patients who are being treated with somatostatin and bromocriptine; 2. Patients with other intracranial organic diseases; 3. Pregnant women and children who cannot express; 4. Patients with other malignant tumors; 5. Participate in other clinical research in the same period; 6. Patients with severe medical complications, such as heart, lung, kidney, liver and other diseases, severe hypertension or poor blood pressure control, hyperglycemia, blood diseases; 7. Those with mental illness who cannot cooperate well with the experiment; 8. Patients with acute infection or open wounds; 9. Acetaminophen is contraindicated (hemolytic anemia, severe liver and kidney dysfunction) or allergic to its components; 10. Patients with contraindications to transcranial magnetic stimulation: patients or users who have implanted cardiac pacemakers, implantable defibrillators and neurostimulators together; those who have a history of epilepsy; wear electronic products (such as insulin Pumps, Holter, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the degree of headache;Improvement of quality of life (QOL); | — |
Secondary
| Measure | Time frame |
|---|---|
| The decrease of acetaminophen doses; | — |
Countries
China
Contacts
Public ContactMin He
Huashan Hospital
Outcome results
None listed